Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice

Antimicrobial Agents and Chemotherapy
N J AjamiL Chesnel

Abstract

Clostridium difficile infection (CDI), a common cause of hospital-acquired infections, typically occurs after disruption of the normal gut microbiome by broad-spectrum antibiotics. Fidaxomicin is a narrow-spectrum antibiotic that demonstrates a reduced impact on the normal gut microbiota and is approved for the treatment of CDI. To further explore the benefits of this property, we used a murine model to examine the effects of fidaxomicin versus vancomycin on gut microbiota and susceptibility to C. difficile colonization while tracking microbiota recovery over time. Mice were exposed to fidaxomicin or vancomycin by oral gavage for 3 days and subsequently challenged with C. difficile spores at predetermined time points up to 21 days postexposure to antibiotics. Fecal samples were subsequently collected for analysis. Twenty-four hours postchallenge, mice were euthanized and the colon contents harvested. The microbiota was characterized using 16S rRNA gene sequencing. All fidaxomicin-exposed mice (except for one at day 8) were resistant to C. difficile colonization. However, 9 of 15 vancomycin-exposed mice were susceptible to C. difficile colonization until day 12. All vancomycin-exposed mice recovered colonization resistance by da...Continue Reading

References

Jul 24, 2002·The American Journal of Gastroenterology·Lynne V McFarlandChristina M Surawicz
Jan 22, 2004·Bioinformatics·Emmanuel ParadisKorbinian Strimmer
Oct 6, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jacques PépinLuc Lanthier
Apr 19, 2006·Gastroenterology·Seema Maroo, J Thomas Lamont
Dec 22, 2006·Nature·Ruth E LeyJeffrey I Gordon
Jan 18, 2008·The Journal of Infectious Diseases·Ju Young ChangVincent B Young
Oct 31, 2008·The New England Journal of Medicine·Ciarán P Kelly, J Thomas LaMont
Aug 17, 2010·Bioinformatics·Robert C Edgar
Feb 4, 2011·The New England Journal of Medicine·Thomas J LouieUNKNOWN OPT-80-003 Clinical Study Group
Aug 4, 2011·Expert Review of Anti-infective Therapy·Kathleen M Mullane, Sherwood Gorbach
Nov 24, 2011·The American Journal of Gastroenterology·Sahil KhannaAlan R Zinsmeister
Jul 7, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michelle M NerandzicCurtis J Donskey
Jul 7, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas J LouieWalter Krulicki
Jul 7, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Fernanda C LessaL Clifford McDonald
Nov 7, 2012·Mayo Clinic Proceedings·Sahil Khanna, Darrell S Pardi
Nov 30, 2012·Nucleic Acids Research·Christian QuastFrank Oliver Glöckner
Mar 13, 2013·Antimicrobial Agents and Chemotherapy·Kevin A BrownDavid N Fisman
Apr 27, 2013·The Journal of Antimicrobial Chemotherapy·Abhishek DeshpandeCurtis J Donskey
Jul 5, 2013·Clinical Microbiology Reviews·Itzhak BrookEllie J C Goldstein
Dec 11, 2013·The Journal of Antimicrobial Chemotherapy·Claudia Slimings, Thomas V Riley
Oct 4, 2014·American Journal of Infection Control·Kelly R RevelesChristopher R Frei
Jul 16, 2015·The New England Journal of Medicine·Daniel A Leffler, J Thomas Lamont
Jul 16, 2015·The New England Journal of Medicine·Emily G McDonald, Todd C Lee
Jul 16, 2015·The New England Journal of Medicine·Sam K SharmaParul J Shukla
Nov 14, 2015·Expert Review of Gastroenterology & Hepatology·Maria O'Sullivan
Nov 20, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Caroline Sheitoyan-PesantLouis Valiquette
Apr 12, 2016·Annals of Gastroenterology : Quarterly Publication of the Hellenic Society of Gastroenterology·Andrew Ofosu
Jul 4, 2017·Annals of Internal Medicine·Sameer D Saini, Akbar K Waljee

❮ Previous
Next ❯

Citations

Jul 1, 2020·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Sumbal BabarJonathan Moorman
Aug 9, 2020·Advances in Therapy·Glorijoy Shi En TanDavid Chien Lye
Dec 31, 2020·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·L BrubakerG Van Buren
Mar 23, 2021·Therapeutic Advances in Gastroenterology·Kanika Sehgal, Sahil Khanna
Apr 4, 2021·Biomedicines·Ali MohamedIrina V Pinchuk
May 21, 2019·JAC-antimicrobial Resistance·Farah ShahiJames Chong
Jul 8, 2021·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Chun-Wei ChiuYuan-Pin Hung
Mar 15, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andrew M SkinnerStuart Johnson
Sep 23, 2020·Journal of Medicinal Chemistry·George A NaclerioHerman O Sintim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.